welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Safety and Efficacy of P-188 NF in DMD Patients

key information

study id #: NCT03558958

condition: Duchenne Muscular Dystrophy

status: suspended


This is an open-label study to evaluate the safety, tolerability and efficacy of daily, subcutaneous dosing with P-188 NF (Carmeseal-MD™) in non-ambulatory boys with Duchenne Muscular Dystrophy (DMD). This study will determine if continuous treatment with Carmeseal-MD™ can maintain or improve pulmonary function, and skeletal and cardiac muscle function, compared to baseline, in boys 12-25 years of age.

intervention: P-188 NF

mechanism of action: Membrane-sealing poloxamer to repair membrane instabilities

results: https://clinicaltrials.gov/ct2/show/results/NCT03558958

last updated: November 28, 2019